Epilepsy Patients Show Amyloid-Independent Tau Deposition Linked to Clinical Severity

Tau protein accumulation is a well-established hallmark of neurodegenerative conditions, traditionally associated with Alzheimer's disease and chronic traumatic encephalopathy [1, 2]. While clinicians have long recognized the cognitive and structural decline that can accompany chronic epilepsy, the underlying molecular drivers of this progression remain poorly defined [3]. Recent evidence suggests that blood-brain barrier dysfunction and reactive astrogliosis, the defense response of astrocytes to central nervous system injury, common in seizure disorders may create a permissive environment for proteinopathy [4, 5, 3]. Furthermore, the interplay between systemic inflammation and microglial activation, the immune response of the brain's resident macrophages, is increasingly viewed as a contributor to accelerated brain aging [6, 7, 8]. To investigate whether these neurodegenerative processes manifest as measurable tau deposition, researchers recently utilized [9]flortaucipir positron emission tomography, a radiopharmaceutical imaging technique that binds to aggregated tau, in a cohort of 75 patients with epilepsy [10].